The clinical trial for ABO2203, an mRNA encoding CD19/CD3 T cell engager, is sponsored by Ruijin Hospital and aims to address refractory autoimmune diseases, a significant unmet medical need. The trial's focus on patients who have shown inadequate responses to standard of care (SoC) positions it strategically within a competitive landscape that includes existing biologics and emerging therapies targeting autoimmune conditions. The potential for a novel mRNA-based therapy could provide a competitive edge, especially if preliminary efficacy results are favorable. The estimated timeline for primary completion in November 2027 suggests a pathway for potential market entry by 2028, contingent upon successful outcomes and regulatory approvals.